Clinical trial
Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)
NCT00326625 · Teva Pharmaceutical Industries, Ltd., Industry · Completed
Key facts
| NCT number | NCT00326625 |
|---|---|
| Title | Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS) |
| Official title | A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of 40 mg Glatiramer Acetate Injection in Subjects With Amyotrophic Lateral Sclerosis (ALS) |
| Lead sponsor | Teva Pharmaceutical Industries, Ltd., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Amyotrophic Lateral Sclerosis |
| Intervention type | Drug |
| Interventions | 40 mg glatiramer acetate, Placebo |
| Enrollment | 366 |
| Start date | Jul 27, 2006 |
| Primary completion | Jun 17, 2008 |
| Completion | Jun 17, 2008 |
| First posted | May 17, 2006 |
| Last update posted | Aug 3, 2022 |
| Countries | Belgium, France, Germany, Israel, Italy, United Kingdom |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: